Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca

Johnson & Johnson

Merck

Pfizer

The candidates belong to five companies, Moderna, AstraZeneca, J&J, Merck and Pfizer.

Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report

Inovio Pharmaceuticals

Novavax

As companies race to produce a coronavirus vaccine, half of Americans may not be interested, and that haste may be part of the reason.

Could the Rush to a Vaccine Hurt Coronavirus Stocks?

BioNTech SE

The White House reportedly plans to route extra federal funds and other assistance to the companies developing those potential SARS-CoV-2 vaccines.

Report: Trump Administration Picks 5 Coronavirus Vaccine Candidates to Support

With demand sky-high for a coronavirus vaccine, it was only natural that MRNA stock jumped higher on Moderna’s encouraging early stage clinical trial results. However, its questionable practices are now coming into closer view.

Moderna May Not Be What Speculators Thought

Positive data from a coronavirus vaccine trial drove share gains.

Why Moderna Shares Rose 33.7% in May

GlaxoSmithKline

Dozens of drugmakers are developing COVID-19 vaccines and gearing up to produce billions of doses each year.

Is a COVID-19 Vaccine Supply Glut on the Way?

Moderna said that it commenced stage 2 trials for its new Coronavirus vaccine candidate mRNA-1273 last week. The company intends to enroll a total of 600 participants in the study, up from 45 participants in the phase 1 study.

What To Expect As Moderna’s Covid-19 Vaccine Commences Phase 2 Trials

Dr. Anthony Fauci Tuesday said the Phase 3 trial of Moderna’s experimental COVID-19 vaccine will begin in July and include study of 30,000 patients.

Fauci: Moderna’s Phase 3 Covid-19 Vaccine Trial Will Include 30,000 Young And Old Individuals

NEW YORK, June 2, 2020 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA). Investors who purchased Moderna securities are encouraged to obtain...

MRNA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Moderna, Inc. Investigation and Encourages Investors to Contact the Firm

Positive results and a key supply agreement for Moderna highlight the bull case for MRNA stock as a promising coronavirus play.
The post Moderna Is Still Worth Investing In Before a Vaccine Is Found appeared first on InvestorPlace.

Moderna Is Still Worth Investing In Before a Vaccine Is Found

White House Coronavirus Task Force lead member Anthony Fauci in an interview with STAT on Monday said he was disappointed with the way Moderna Inc.

Fauci Reiterates Moderna Vaccine Data Is 'Cautiously Optimistic,' Expects Pfizer's Results To Be The Same

SAN FRANCISCO, June 1, 2020 /PRNewswire/ -- Hagens Berman urges investors in Moderna, Inc. (NASDAQ: MRNA) to submit their losses now to learn if they qualify to recover their investment losses. Relevant Holding Period: Before June 1, 2020 Visit: www.hbsslaw.com/investor-fraud/MRNA Contact...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Possible Securities Fraud and Insider Trading, Encourages Moderna, Inc. (MRNA) Investors with Significant Losses to Contact Firm

Moderna Inc (NASDAQ: MRNA) announced late Friday it has dosed the first participants in a Phase 2 trial of its mRNA vaccine, codenamed mRNA-1273, against SARS-CoV-2, the virus that causes COVID-19.

Moderna Doses First Participants In Phase 2 Study Of Coronavirus Vaccine

The vaccine is advancing through clinical trials at lightning speed.

Moderna Starts a Phase 2 Clinical Trial for Its COVID-19 Vaccine

Moderna set off a frenzy on Wall Street earlier this month when it announced positive, preliminary results from its coronavirus vaccine trial. As the hype grew, the young biotech company and its leading investor wasted no time capitalizing on the briefly surging stock price.

Moderna's coronavirus vaccine announcement set off a frenzy on Wall Street. Now some are calling for an investigation

Moderna shares have dropped from a record high. Here’s what hurt the stock -- and what could lead to recovery.

Are Moderna’s Coronavirus Gains Over?

It's far too early to get excited about the company's potential COVID-19 vaccine.

Investors Are Jumping the Gun on Moderna's Vaccine Results

The biotech is ramping up its coronavirus vaccine production capabilities.

Why Moderna Stock Jumped 10.7% Today

Moderna Inc. MRNA, +10.73% announced Friday afternoon that the latest study of its potential COVID-19 vaccine has begun.

Moderna begins new COVID-19 vaccine study

Moderna has become the stock market's great hope for a Covid-19 vaccine, but there are dozens of other candidates.
The post Why Moderna Stock Is Still Only Good for Speculators appeared first on InvestorPlace.

Why Moderna Stock Is Still Only Good for Speculators

Moderna Inc (NASDAQ: MRNA) is progressing rapidly in its program to develop an mRNA vaccine for SARS-CoV-2, codenamed mRNA-1273.

Moderna Expands Deal With CDMO To Source Raw Material For Coronavirus Vaccine

Arcturus Therapeutics

Dynavax Technologies

iBio

Sorrento Therapeutics Inc

A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.

7 Red-Hot Biotech Stocks Racing to Develop a Coronavirus Vaccine

Data from the Phase 1 trial of Moderna's coronavirus vaccine was mixed, making MRNA stock risky at its current levels.
The post Why Moderna Stock Looks Quite Risky appeared first on InvestorPlace.

Why Moderna Stock Looks Quite Risky

The biotech's coronavirus vaccine reportedly made some people sick.

Why Moderna Stock Dropped Today (MRNA)

Shares of biotechs racing to make coronavirus vaccines, including Moderna Inc , fell about 10% on Wednesday, as investor concerns grew about the prospects of the experimental products that are still in early stages of development.

News for Moderna Stock (MRNA)